Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Lexeo Therapeutics, Inc. Common Stock

LXEO

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Last trade $3.01
Day change -$0.225 (-6.97%)
Day range $2.96 – $3.39
Volume 2,409,051
Market cap $265M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$265.14M
Price / earnings
—
Price / book
1.13×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.82×

Profitability

Earnings per share
-$1.06
Return on assets
-34.24%
Return on equity
-37.12%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
13.89×
Quick ratio
13.89×
Cash ratio
5.92×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$88.7M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LXEO, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$8.99M$6.63M$6.91M$5.95M$15.97M$16.63M$9.02M$8.12M
Research and development$19.03M$15.7M$16.21M$15.7M$14.72M$17.17M$18.37M$23.42M
Total operating expenses$28.02M$22.33M$23.12M$21.65M$30.69M$33.81M$27.38M$31.54M
Operating income-$28.02M-$22.33M-$23.12M-$21.65M-$30.69M-$33.81M-$27.38M-$31.54M
Interest expense-$14K-$17K-$20K-$22K-$25K-$28K-$30K-$35K
Income before taxes-$25.87M-$20.2M-$20.92M-$20.28M-$26.1M-$32.66M-$25.92M-$29.49M
Income taxes$0$0$0$0$0$0$0$0
Net income-$25.87M-$20.2M-$20.92M-$20.28M-$26.1M-$32.66M-$25.92M-$29.49M
Net income attributable to common shareholders-$25.87M-$20.2M-$20.92M-$20.28M-$26.1M-$32.66M-$25.92M-$29.49M
EBITDA-$27.95M-$22.26M-$23.04M-$21.74M-$30.63M-$33.75M-$27.31M-$31.63M
Basic earnings per share-$0.30-$0.25-$0.27-$0.33-$0.60-$0.99-$0.78-$0.89
Diluted earnings per share-$0.30-$0.25-$0.27-$0.33-$0.60-$0.99-$0.78-$0.89

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026

Lexeo Therapeutics announced it will report Q3 2026 financial results and provide a business update on the HEROIC-PKP2 Phase I/II clinical trial of LX2020, an AAV-based gene therapy for PKP2 arrhythmogenic cardiomyopathy, on November 16, 2026. The company is advancing a portfolio of therapeutic candidates for cardiovascular and neurological genetic diseases with high unmet need.

GlobeNewswire Inc.

Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM

Lexeo Therapeutics announced an educational investor event on October 21, 2026, featuring discussions on clinical endpoints and outcome measures for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM). The event will include Lexeo's Chief Medical Officer and a specialist from Cleveland Clinic discussing the clinical significance of key assessments and treatment response evaluation for this genetic heart disease.

GlobeNewswire Inc.

Lexeo Therapeutics to Participate in the Chardan Healthcare Conference

Lexeo Therapeutics, a clinical-stage biotech company, announced it will participate in a fireside chat at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The company is focused on developing genetic disease treatments, including LX2006 for Friedreich ataxia and LX2020 for arrhythmogenic cardiomyopathy.

GlobeNewswire Inc.

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

Lexeo Therapeutics announced that its abstract for LX2006, an AAV-based gene therapy for Friedreich ataxia, has been accepted for oral presentation at the MDS 2026 Congress in Seoul. The presentation will highlight early stabilization or improvement in mFARS scores in LX2006-treated participants compared to propensity-matched controls, along with new subscore analyses. LX2006 has received multiple FDA designations including Breakthrough Therapy and Orphan Drug status.

GlobeNewswire Inc.

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics reported positive interim Phase I/II data for LX2020, an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. The therapy demonstrated good tolerability across 10 participants, with 93-162% increases in PKP2 protein expression and stabilization or improvement in arrhythmia burden in the majority of participants. The company plans to complete 12-month data collection by Q4 2026 and engage with regulators in 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.